TRYMEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRYMEX (TRYMEX).
TRYMEX is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuron, enhancing neurotransmission in the central nervous system.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4, with minor contributions from CYP2C9 and CYP2C19. The major metabolite is the active S-enantiomer, which is further metabolized. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of dose; biliary/fecal elimination contributes 20-30%, with <5% as metabolites. |
| Half-life | Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 30-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | 90-95% bound, primarily to alpha-1-acid glycoprotein and albumin. |
| Volume of Distribution | Vd = 0.8-1.2 L/kg, indicating moderate tissue distribution with higher concentrations in well-perfused organs. |
| Bioavailability | Oral: 75-85% (first-pass effect minimal); Intramuscular: 90-100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 6-8 hours; Intramuscular: 8-10 hours. Duration prolonged in hepatic impairment. |
| Molecular Weight | 375.4 |
Adults: 500 mg orally twice daily or 1 g intravenously once daily.
| Dosage form | OINTMENT |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 30-50 mL/min: 500 mg every 12 h; CrCl 15-29 mL/min: 500 mg every 24 h; CrCl <15 mL/min: 500 mg every 48 h. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | Children >12 years: same as adult; 6-12 years: 10 mg/kg twice daily; <6 years: not established. |
| Geriatric use | No specific adjustment except based on renal function; monitor for increased adverse effects. |
| 1st trimester | Contraindicated due to risk of teratogenicity; animal studies show fetal malformations, no controlled human data. |
| 2nd trimester | Not recommended; limited data but potential risk of fetal harm outweighs benefits. |
| 3rd trimester | Avoid use near term due to risk of adverse effects (e.g., premature closure of ductus arteriosus, oligohydramnios). |
Clinical note
Comprehensive clinical and safety monograph for TRYMEX (TRYMEX).
| Placental transfer | Crosses placenta; documented in human studies (cord blood levels 10-30% of maternal serum). |
| Breastfeeding | Excreted into breast milk in low levels; potential for adverse effects in nursing infants (e.g., diarrhea, rash). Use caution and monitor infant. Discontinue if infant shows signs of toxicity. |
■ FDA Black Box Warning
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. Monitor closely for worsening and emergence of suicidal thoughts and behaviors.
| Serious Effects |
Hypersensitivity to TRYMEX or any excipientSevere hepatic impairment (Child-Pugh C)Concurrent use with MAO inhibitorsHistory of serotonin syndromePregnancy (except limited gestational age in emergencies)
| Precautions | Serotonin syndrome, Suicidal thoughts and behaviors, Bleeding risk (especially with NSAIDs or aspirin), Activation of mania/hypomania, Seizure threshold lowering, Angle-closure glaucoma, Hyponatremia, QT prolongation (dose-dependent), Sexual dysfunction, Discontinuation syndrome upon abrupt withdrawal |
| Food/Dietary | Avoid grapefruit and grapefruit juice as it may increase TRYMEX levels. Limit alcohol intake as it can exacerbate CNS depression. No significant interaction with other foods; taking with food may reduce GI upset. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | TRYMEX is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of fetal growth restriction, preterm birth, and neonatal adaptation syndrome. Use only if no safer alternative and benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and respiratory status. Fetal monitoring: ultrasound for growth and anatomy, non-stress test or biophysical profile in third trimester. Neonatal monitoring: observe for withdrawal (irritability, tremors, poor feeding). |
| Fertility Effects | TRYMEX may impair female fertility by disrupting menstrual cyclicity and ovulation. In males, may reduce sperm motility and count. Effects are reversible upon discontinuation. |
| Clinical Pearls | TRYMEX is a selective serotonin reuptake inhibitor (SSRI) indicated for major depressive disorder and generalized anxiety disorder. Monitor for serotonin syndrome when co-administered with other serotonergic agents. Titrate dose slowly to minimize activation side effects; elderly patients may require lower doses due to reduced clearance. Assess for hyponatremia, especially in volume-depleted patients. Discontinuation syndrome is common; taper gradually over weeks. |
| Patient Advice | Take exactly as prescribed; do not adjust dose without consulting your doctor. · May take 2-4 weeks to feel full therapeutic benefit; continue medication even if feeling well. · Avoid alcohol and grapefruit juice; they can increase side effects or alter drug levels. · Report any signs of serotonin syndrome: agitation, hallucinations, rapid heart rate, fever, muscle stiffness, or loss of coordination. · Do not stop abruptly; this can cause withdrawal symptoms like dizziness, nausea, headache, and anxiety. · Use caution when driving or operating machinery until you know how this medication affects you. · Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Store at room temperature away from moisture and heat. |